LINEZOLID PRESCRIPTION PATTERN- IDENTIFYING THE USE TO RATIONALIZE THE PRACTICE

Author(s)

Reis HP1, Candido D2, Magalhaes D3, Vieira JB3, Sartori DP3, Rodrigues JL2, Rodrigues EX3, Gurgel Filho N3, Viana A3, Chaves E3, Bastos A3, Albuquerque I3
1UFC, Fortaleza, Brazil, 2Universidade Federal do Ceará, Fortaleza, Brazil, 3UNIMED Fortaleza, Fortaleza, Brazil

OBJECTIVES: Linezolid is an important antimicrobial strategy to combat methicillin-resistant Staphylococcus aureus (MRSA). However, it should be used with caution due to its high cost and to avoid the development of resistant strains. This study sought to determine the pattern of use of Linezolid in a large hospital in Fortaleza, Brazil. METHODS: This was a cross-sectional study carried out from 2013 to 2014, in which data were collected from the medical records of 170 patients admitted to medical wards and intensive care units of a general hospital and that were in use of Linezolid. The pharmacotherapeutic and microbiological parameters followed the Antimicrobial Stewardship Guideline (Infectious Diseases Society of America, 2012) by pharmacist and medical infectious disease team. For the calculation of the direct cost, the electronic source Brasíndice was used RESULTS: The patients were in use of this antimicrobial had a mean age of 74.5 years and 56% were female. The most isolated bacteria were Staphylococcus aureus (13; 72%), Enterococcus (4; 22%), Streptococcus pneumoniae (1; 6%) and the most verified types of infection were pulmonary (137 / 64.32%), urinary (22 / 10.33%) and skin (9/4.22%). The average load time was 11.3 days. The overall cost of the therapy with Linezolid was $216,075.41.   CONCLUSIONS: Linezolid is strategic in the treatment against MRSA, especially in pneumonia, but should be used rationally to avoid adverse effects and increase of unnecessary costs. Thus, the determination of its pattern of use was a fundamental step to achieve better clinical outcomes in the multidisciplinary team setting.

Conference/Value in Health Info

2015-05, ISPOR 2015, Philadelphia, PA, USA

Value in Health, Vol. 18, No. 3 (May 2015)

Code

PIN24

Topic

Epidemiology & Public Health

Topic Subcategory

Safety & Pharmacoepidemiology

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×